ClinicalTrialsFinder
RecruitingPhase 2NCT07470983

A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

Sponsor

Shandong Suncadia Medicine Co., Ltd.

Enrollment

60 participants

Start Date

Apr 23, 2026

Study Type

INTERVENTIONAL

Conditions

Primary Aldosteronism

Summary

This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HRS-1780 Tablets and a drug called Placebo for people with primary aldosteronism. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHRS-1780 Tablets

HRS-1780 Tablets

DRUGPlacebo

Placebo

Locations(2)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07470983

Related Trials

Diagnosing Variable Primary Aldosteronism.

NCT057657861 location

Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test

NCT076918011 location

Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism

NCT076889281 location

Study on the Diagnostic Cut-off Point of 24-hour Urinary Aldosterone Measured by Liquid Chromatography-Tandem Mass Spectrometry in the Diagnosis of Primary Aldosteronism in the Oral Sodium Loading Test

NCT076351341 location

Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism

NCT076214581 location